Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher says its COVID-19 tests accurately detects Omicron variant

11/29/2021 | 12:50pm EST

Nov 29 (Reuters) - Thermo Fisher Scientific Inc said on Monday its COVID-19 diagnostic tests can accurately detect the new coronavirus variant Omicron that has prompted several countries to shut their borders.

The World Health Organisation (WHO) last week classified the Omicron variant as a SARS-CoV-2 "variant of concern," saying it may spread more quickly than other forms.

Thermo Fisher's TaqPath COVID-19 assays can report accurate results even in the case where one of the gene targets is impacted by a mutation, the company said in a statement. "This assay can be used not only to successfully detect COVID-19 but… it can also be used as a proxy for the variant," Mark Stevenson, chief operating officer at Thermo Fisher Scientific, said in an interview.

Stevenson said this is the only COVID-19 diagnostic test that is both authorized by the U.S. Food and Drug Administration and can be used to indicate if a case is caused by the Omicron variant.

He added that Thermo is prepared to increase its production of tests to meet demand from countries in Africa and elsewhere as they work to track the spread of the new variant.

Other COVID-19 tests, including from Roche Holding AG and Abbott Laboratories, can also be used to diagnose positive cases of COVID-19 caused by the variant, though only Thermo Fisher has so far confirmed that its test can be used to help identify the variant.

"We have conducted an assessment of the Omicron variant and we’re confident our antigen and PCR tests can" identify positive cases of COVID-19 caused by Omicron, a spokeswoman for Abbott said.

Test samples must still be sent to a lab for sequencing to confirm that the case was caused by Omicron and not another variant with similar features, such as the Alpha variant, Stevenson said.

Omicron, which was first detected in Southern Africa, has now been confirmed in Australia, Belgium, Botswana, Britain, Denmark, Germany, Hong Kong, Israel, Italy, the Netherlands, France, South Africa, and the United States' neighbor to the north, Canada.

The WHO said it was working with technical experts to understand the potential impact of the variant on existing countermeasures against COVID-19, including vaccines. (Reporting by Radhika Anilkumar in Bengaluru and Carl O'Donnell in New York; Editing by Arun Koyyur and Andrea Ricci)

ę Reuters 2021
All news about ROCHE HOLDING AG
01/26PTC Therapeutics - FDA Grants Evrysdi Priority Review Based on Results from Treating Pr..
01/26ROCHE HOLDINGS AG : Deutsche Bank keeps its Buy rating
01/26ROCHE HOLDINGS AG : Goldman Sachs reiterates its Buy rating
01/26ROCHE HOLDINGS AG : JP Morgan reiterates its Neutral rating
01/25The Lancet Publishes Studies Showing Genentech's Faricimab Improved and Maintained Visi..
01/25Roche's Spinal Muscular Atrophy Drug Wins US FDA Priority Review
01/25Genentech's Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-Sympto..
01/25Roche's Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomati..
01/25Roche Announces U.S. Food and Drug Administration Grants Evrysdi Priority Review for Tr..
01/24US FDA Restricts Use of Eli Lilly, Regeneron's COVID-19 Treatments
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Sales 2021 62 366 M 67 426 M 67 426 M
Net income 2021 15 017 M 16 236 M 16 236 M
Net Debt 2021 6 627 M 7 165 M 7 165 M
P/E ratio 2021 19,4x
Yield 2021 2,84%
Capitalization 282 B 306 B 305 B
EV / Sales 2021 4,63x
EV / Sales 2022 4,60x
Nbr of Employees 101 465
Free-Float -
Duration : Period :
Roche Holding AG Technical Analysis Chart | ROG | CH0012032048 | MarketScreener
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 349,10 CHF
Average target price 407,45 CHF
Spread / Average Target 16,7%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Pascale Schmidt Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-7.91%306 143
JOHNSON & JOHNSON-1.57%443 277
PFIZER, INC.-10.23%297 538
ABBVIE INC.-0.86%237 303
NOVO NORDISK A/S-15.89%213 450